Professional development Vacancies

Overview of recommendations adopted by the PRAC on signals discussed at the meeting of October 23-26, 2020

27.11.2020 2608 views

medicinal products containing lamotrigine – photosensitivity

Based on the review of data on the risk of photosensitivity with lamotrigine, the PRAC agreed that registration certificate holders for medicinal products containing lamotrigine must, within 2 months, submit variations to update the instructions for medical use as indicated below (new text underlined):

  • into the "Special warnings and precautions for use" section of the instructions

Skin rash (new text will be added at the end of the paragraph)

[…]

There have also been reports of photosensitivity reactions associated with the use of lamotrigine (see section “Adverse reactions”). In several cases, the reaction occurred with the use of a high dose (400 mg or more), after a dose increase or rapid titration. If a patient with signs of photosensitivity (for example, severe sunburn) is suspected of having lamotrigine-related photosensitivity, discontinuation of treatment should be considered. If continuing lamotrigine treatment is considered clinically justified, the patient should be advised to avoid exposure to sunlight and artificial ultraviolet light and to observe protective measures (for example, the use of protective clothing and sunscreens).

  • in the “Adverse reactions” section of the instructions, add the reaction of photosensitivity. to the tabulated list of reactions with the frequency “uncommon”

Linkhttps://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-october-2020-prac-meeting_en.pdf

Перелік лікарських засобів, що містять lamotrigine і дозволені для медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 25.11.2020)